Tariq Parvez.
Study of the Effect of Letrozole in Postmenopausal Patients with Advanced Breast Cancer Resistant to Tamoxifen.
J Coll Physicians Surg Pak Jan ;10(1):20-3.

A study on 25 postmenopausal patients suffering from advanced breast cancer resistant to tamoxifen while on treatment or recurrence after its use was done by treating them with Letrozole for six months and in 15 patients by completing one year with Letrozole. Toxicity from Letrozole was minimum and easily manageable. In the first six months (in 25 patients) overall response was 28%, complete response 4% and partial response 24%. Disease was stable in 24% of cases so the overall clinical benefit was in 52%. At the end of one year of treatment (in 15 patients) the overall response was 20% with no complete response and 20% partial response. There was no change in 13% of patients so collectively clinical benefit was in 33% of cases. There was no benefit in those who had disease progression within 6 months of treatment and then by continuing the drug for further period. Those with partial response and no change at 6 months clearly benefited by continuing the drug further.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com